Literature DB >> 21950448

Prediction of additional lymph node positivity and clinical outcome of micrometastases in sentinel lymph nodes in cutaneous melanoma: a multi-institutional study of 450 patients in Japan.

Kenjiro Namikawa1, Naoya Yamazaki, Yasuo Nakai, Hironobu Ihn, Yasushi Tomita, Hisashi Uhara, Tatsuya Takenouchi, Yoshio Kiyohara, Yoichi Moroi, Yuhei Yamamoto, Fujio Otsuka, Hideki Kamiya, Hajime Iizuka, Naohito Hatta, Takafumi Kadono.   

Abstract

Various microscopic classifications of metastatic sentinel lymph nodes (SLN) have been reported along with predictors of additional lymph node positivity and their correlations with the prognosis. The purpose of this study was to re-evaluate these classifications in the Japanese population. We selected the following three classifications, based on the procedural simplicity of the measurements: maximum diameter (maximum diameter of the largest tumor lesion in the SLN; <0.1, 0.1-1.0, >1.0 mm), invasion depth (depth of tumor invasion measured from the capsule in the SLN; SI ≤ 0.3 mm, SII >0.3 to ≤ 1.0 mm, SIII >1.0 mm), and microanatomic location (microanatomic location of the tumor deposits within the SLN; "subcapsular", "parenchymal", "combined", "multifocal", "extensive"). A retrospective study, using prescribed survey forms, was carried out. Among the 450 patients, including the 149 cases with SLN metastasis, an additional lymph node positivity rate of 0% could be predicted only in patients with a maximum diameter category of less than 0.1 mm. As compared with that in the SLN metastasis-negative cases, however, the prognosis was poorer in cases with SLN metastasis, even those with lesions falling under the maximum diameter category of less than 0.1 mm, invasion depth category of SI (≤ 0.3 mm) and microanatomic location category of subcapsular. The prognosis is particularly poor for the microanatomic location category of extensive, which should thus be regarded as a macrometastasis. A prospective study with standardized procedures, including pathological evaluation, is needed in order to confirm our conclusion.
© 2011 Japanese Dermatological Association.

Entities:  

Mesh:

Year:  2011        PMID: 21950448     DOI: 10.1111/j.1346-8138.2011.01318.x

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


  5 in total

1.  Frequency of level II and III axillary nodes metastases in patients with positive sentinel lymph nodes in melanoma: a multi-institutional study in Japan.

Authors:  Arata Tsutsumida; Akira Takahashi; Kenjiro Namikawa; Naoya Yamazaki; Hisashi Uhara; Yukiko Teramoto; Tatsuya Takenouchi; Satoshi Fukushima; Kenji Yokota; Jiro Uehara; Shigeto Matsushita; Yoshitsugu Shibayama; Naohito Hatta; Yuri Masui; Hiroshi Uchi; Yasuhiro Fujisawa; Dai Ogata
Journal:  Int J Clin Oncol       Date:  2016-01-13       Impact factor: 3.402

2.  Limitation of indocyanine green fluorescence in identifying sentinel lymph node prior to skin incision in cutaneous melanoma.

Authors:  Kenjiro Namikawa; Arata Tsutsumida; Ryota Tanaka; Junji Kato; Naoya Yamazaki
Journal:  Int J Clin Oncol       Date:  2013-02-01       Impact factor: 3.402

3.  Sentinel Lymph Node Biopsy Was Associated With Favorable Survival Outcomes For Patients With Clinically Node-Negative Asian Melanoma.

Authors:  John Wen-Cheng Chang; Yen-Lin Huang; Yao-Yu Chang; Yung-Feng Lo; Tsung-Ying Ho; Yi-Ting Huang; Huan-Wu Chen; Chiao-En Wu
Journal:  Cancer Manag Res       Date:  2019-11-14       Impact factor: 3.989

4.  Long-term survival analysis and clinical follow-up in acral lentiginous malignant melanoma undergoing sentinel lymph node biopsy in korean patients.

Authors:  Su-Young Jeon; Jin-Woo Hong; Suee Lee; Sung Yong Oh; Young-Seoub Hong; Ki-Ho Kim; Ki-Hoon Song
Journal:  Ann Dermatol       Date:  2014-04-30       Impact factor: 1.444

5.  The sentinel node invasion level (SNIL) as a prognostic parameter in melanoma.

Authors:  Lutz Kretschmer; Christina Mitteldorf; Simin Hellriegel; Andreas Leha; Alexander Fichtner; Philipp Ströbel; Michael P Schön; Felix Bremmer
Journal:  Mod Pathol       Date:  2021-06-15       Impact factor: 7.842

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.